REGENXBIO Inc. (RGNX)
| Market Cap | 520.30M +13.5% |
| Revenue (ttm) | 170.44M +104.5% |
| Net Income | -193.88M |
| EPS | -3.76 |
| Shares Out | 51.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,581,495 |
| Open | 10.71 |
| Previous Close | 10.55 |
| Day's Range | 9.96 - 11.36 |
| 52-Week Range | 7.35 - 16.19 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 28.75 (+185.22%) |
| Earnings Date | May 14, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $28.75, which is an increase of 185.22% from the latest price.
News
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place M...
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will ho...
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
Notice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK, March 26, 2026 /PRNewswire/ -- Institutional investors holding positions in REGENXBIO, Inc. (NASDAQ: RGNX) during the period between ...
Shareholders Sue RGNX Over Gene Therapy Study Claims
A class action lawsuit was filed against REGENEXBIO ($RGNX) on February 13, 2026. The federal securities class action alleges that plaintiffs acquired REGENEXBIO stock at artificially inflated prices ...
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Regenxbio said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement ...
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
REGENXBIO (RGNX) announced newinterim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential gene therapy for Duchenne muscular dystrophy. Trial investigator Carolina Tesi-Rocha, M.D...
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 ye...
REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference
DUPIXENT and EYLEA HD continue to drive strong growth, with new launches and label enhancements supporting momentum. The pipeline is advancing with key readouts expected for LAG-3 in melanoma, geographic atrophy, and PNH, while obesity and hematology programs target significant future opportunities.
REGENXBIO Transcript: Leerink Global Healthcare Conference 2026
Key late-stage programs are advancing toward regulatory milestones, with strong manufacturing capabilities and commercial readiness for a potential 2027 launch. International expansion and strategic partnerships, especially in ophthalmology, are expected to drive growth, while PRVs and milestones provide financial strength.
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $30 from $32 and keeps a Buy rating on the shares following the Q4 report.
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $17 from $18 and keeps an Overweight rating on the shares after the company reported fourth quarter results. Investor…
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
Promise vs. Reality: The REGENXBIO Gene Therapy Performance Gap NEW YORK, March 5, 2026 /PRNewswire/ -- "Very promising results.
Regenxbio price target lowered to $42 from $45 at Stifel
Stifel lowered the firm’s price target on Regenxbio (RGNX) to $42 from $45 and keeps a Buy rating on the shares. The firm notes the company is moving toward pivotal…
REGENXBIO Earnings Call Transcript: Q4 2025
Late-stage programs in DMD, wet AMD, and diabetic retinopathy are advancing, with pivotal data readouts and regulatory filings expected in 2026. Financially, strong cash reserves and anticipated milestones support operations into 2027, while regulatory and safety risks remain key considerations.
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
Reports Q4 revenue $30.3M vs. $21.2M last year. “We are rapidly advancing our late-stage pipeline of gene therapies to treat rare and retinal diseases with significant unmet need, with multiple…
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected earl...
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
ROCKVILLE, Md., March 4, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 Muscul...
REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) se...
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 2, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Fir...
Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program
Leerink notes that Marty Makary, Commissioner of the FDA appeared on CNBC where he defended the agency’s stance on Rare Disease and made some pointed remarks about a specific program…
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m.
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
11:45 EST Court revives Regenxbio (RGNX), UPenn patent suit against Sarepta (SRPT), Bloomberg says
Regenxbio price target lowered to $32 from $34 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $32 from $34 and keeps a Buy rating on the shares after the company received a complete response letter…
Regenxbio price target lowered to $27 from $39 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $27 from $39 and keeps an Outperform rating on the shares. The firm updated its model following…